(redirected from Oligonucleotides)
Also found in: Medical, Encyclopedia.


 (ŏl′ĭ-gō-no͞o′klē-ə-tīd, -nyo͞o′-, ō′lĭ-)
A short polymer of two to twenty nucleotides.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


(Biochemistry) a polymer consisting of a small number of nucleotides
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014


(ˌɒl ɪ goʊˈnu kli əˌtaɪd, -ˈnyu-)

a chain of a few nucleotides.
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
References in periodicals archive ?
Eurofins Genomics and Blue Heron have an inherent connection between their main product segments, oligonucleotides, sequencing and synthetic genes. Growth in the Life Science Industry to Drive the Market for Oligonucleotides Synthesis in the UK
Avidity's platform seeks to combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to potentially overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease.
GeneDesign, a wholly owned Ajinomoto company, provides high quality and scalable custom oligonucleotides for the biopharmaceutical industry.
Antisense oligonucleotides, used in the above study, were found to influence RNA processing and modulate protein expression over 20 years ago and much progress has been made translating these agents into a clinical setting.
[ClickPress, Thu Sep 27 2018] Oligonucleotides are short fragments of nucleic acids and play a major role in drug discovery and molecular diagnostic chip technology.
M2 PHARMA-February 23, 2018-Takeda Collaborates with Wave Life Sciences to Develop Antisense Oligonucleotides for Treatment of Neurological Diseases
They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.
In 2006, professor Masafumi Matsuo (Kobe Gakuin University Department of Medical Rehabilitation) and designated professor Yasuhiro Takeshima (Kobe University Graduate School of Medicine Department of Pediatrics) were the first in the world to demonstrate the effectiveness of anti-sense oligonucleotides to restore dystrophin expression in DMD sufferers through the mechanism known as exon skipping.
While studying the chemistry and biochemistry of oligonucleotides (short sequences of DNA, RNA, and their chemically synthesized analogues), I have often come face-to-face with the frustration that can be caused by forgetting how tightly information and structure are intertwined.
Handbook of analysis of oligonucleotides and related products.